Author | Ernest T. Hawk, MD, MPH


Ernest Hawk Discusses the NCI-Designated Cancer Centers’ Joint Statement on the HPV Vaccine

July 15, 2016

ByErnest T. Hawk, MD, MPH

In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.

Adenocarcinoma of the Esophagus: Risk Factors and Prevention

April 01, 2000

ByElisabeth I. Heath, MD|Arlene A. Forastiere, MD|Paul J. Limburg, MD, MPH|Ernest T. Hawk, MD, MPH

Esophageal cancer, with an estimated number of 12,300 new cases in the year 2000, is relatively uncommon in the United States but produces a high number of annual deaths, estimated at 12,100. Moreover, the incidence of the

Strategies for Identification and Clinical Evaluation of Promising Chemopreventive Agents

October 01, 1996

ByGary J. Kelloff, MD|Ernest T. Hawk, MD, MPH|Charles W. Boone, MD, PhD|Susan G. Nayfield, MD, MSC|Marjorie Perloff, MD|Vernon E. Steele, PhD, MPH|Ronald A. Lubet, PhD|Caroline C. Sigman, PhD

Strategies for chemopreventative drug development are based on the use of well-characterized agents, intermediate biomarkers correlating to cancer incidence, and suitable cohorts for efficacy studies. Since